Table 2. Clinical characteristics and plasma FGF-21 levels of patients with and without PAD.
| PAD(−) | PAD | P value | |
|---|---|---|---|
| (n = 379) | (n = 38) | ||
| Age (years) | 67 ± 10 | 75 ± 6 | < 0.01 |
| Gender (male) | 263 (69%) | 28 (74%) | 0.80 |
| BMI (kg/m2) | 23.7 ± 4.0 | 22.7 ± 3.2 | 0.12 |
| Hypertension | 267 (70%) | 34 (89%) | 0.03 |
| Systolic blood pressure (mmHg) | 131 ± 20 | 131 ± 30 | 0.92 |
| Diabetes mellitus | 89 (23%) | 14 (37%) | 0.70 |
| Smoking | 103 (27%) | 14 (37%) | 0.30 |
| Hyperlipidemia | 182 (48%) | 24 (63%) | 0.70 |
| Statin | 125 (33%) | 22 (58%) | < 0.01 |
| LDL-cholesterol (mg/dL) | 113 ± 31 | 113 ± 29 | 0.92 |
| HDL-cholesterol (mg/dL) | 55 ± 14 | 49 ± 11 | 0.01 |
| FGF-21 level (pg/mL) | 30.7 [0.0, 100.5] | 0.0 [0.0, 39.4] | 0.02 |
| FGF-21 < 15.6 pg/mL | 163 (43%) | 24 (63%) | 0.03 |
| CAD | 191 (50%) | 33 (87%) | < 0.01 |
| 1-VD | 83 (22%) | 9 (24%) | 0.95 |
| 2-VD | 59 (16%) | 6 (6%) | 0.90 |
| 3-VD | 49 (13%) | 18 (47%) | < 0.01 |
| Antiplatelet drugs | 171 (45%) | 25 (66%) | 0.03 |
Data represent the mean ± SD or the number (%) of patients, with the exception of FGF-21 level which is presented as the median value and interquartile range.